Benefits from mianserin augmentation of fluoxetine in patients with major depression non-responders to fluoxetine alone
The DOI matches its OpenAlex record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To assess, in depressed patients, the clinical benefit of mianserin augmentation of fluoxetine or the the benefit of switching treatment from fluoxetine to mianserin. METHOD: In a 6-week double-blind study we compared the therapeutic efficiency and tolerance of mianserin 60 mg/day (N = 34), mianserin 60 mg/day plus fluoxetine 20 mg/day (N = 32) and continuing fluoxetine 20 mg/day (N = 38) in patients with major depression who did not respond to previous fluoxetine treatment. RESULTS: Intent-to-treat analysis showed that at week 6 the decrease in the Hamilton Depression rating scale score was significantly (P < or = 0.03) greater in the mianserin plus fluoxetine group when compared to the fluoxetine group (effect size 0.665). Switching from fluoxetine to mianserin gave intermediate results. Mianserin augmentation of fluoxetine was well tolerated. CONCLUSION: Mianserin augmentation of fluoxetine in patients non-responders to fluoxetine 20 mg/day increases response to treatment and is well tolerated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Serotonin Reuptake Inhibitor Withdrawal
Coupland, N. J., Bell, C. J., & Potokar, J. P. (1996) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199610000-00003 · Cited by 303
Citalopram withdrawal symptoms
Benazzi, F. (1998) · European Psychiatry · doi:10.1016/s0924-9338(98)80007-2 · Cited by 11
Research works printed but not linked: 24
- Debus JR, 1988, Fluoxetine versus trazodone in the treat‐ment of out‐patients with major depression, J Clin Psychiatry, 49, 422
- 10.1097/00004714-199310000-00002 · DOI · Paper page
- Tignol J, 1993, A double‐blind, randomized fluoxetine‐controlled, multicenter study of paroxetine in the treatment of depression, J Clin Psychopharmacol, 13, 18S, 10.1097/00004714-199312002-00003 · DOI · Paper page
- 10.1007/BF02245454 · DOI
- Bennie EH, 1995, A double blind multicenter trial comparing sertraline and fluoxetine in out‐patients with major depression, J Clin Psychiatry, 56, 229
- 10.1176/ajp.152.10.1500 · DOI · Paper page
- 10.1176/ajp.151.9.1372 · DOI · Paper page
- 10.1097/00004714-199904000-00014 · DOI
- 10.1055/s-2007-979298 · DOI · Paper page
- Klysner R, 1991, Refractory depression, 109
- Lafon‐Lopez L, 1986, Etude de la potentialisation de deux antidépresseurs entre eux. Clomipramine–miansérine. Evalu‐ation clinique et biologique. Actualités psychopharmacologiques, Inf Psychiatr, 9, 1147
- 10.1055/s-2007-1014403 · DOI
- 10.3109/08039489409081375 · DOI
- 10.1097/00002826-199706000-00004 · DOI · Paper page
- 10.1136/jnnp.23.1.56 · DOI · Paper page
- Ferreri M, 1984, Le diagramme HARD, Pratique Med, 33, 39
- Von Frenckell R, 1989, Validation factor‐ielle de l'échelle HARD dans deux groupes de déprimés, L'Encéphale, 15, 423
- 10.1001/archpsyc.1983.01790110077013 · DOI · Paper page
- 10.1192/bjp.162.5.634 · DOI · Paper page
- 10.1001/archpsyc.1993.01820170065008 · DOI · Paper page
- Koyama E, 1996, Identification of human cytochrome P 450 isoforms involved in the stereoselective metabolism of mianserin enantiomers, J Pharmacol Exp Ther, 278, 21, 10.1016/S0022-3565(25)20103-3 · doi:10.1016/s0022-3565(25)20103-3
- 10.1097/00008571-199710000-00005 · doi:10.1097/00008571-199710000-00005
- Schatzberg AF, 1997, Serotonin reuptake inhibitor discontinuation syndrome: a hypothetical definition. Discontinuation consensus panel, J Clin Psy-chiatry, 58, 5
- 10.1007/BF02245452 · DOI
Cited by
Anderson, I., Ferrier, I., Baldwin, R., Cowen, P., Howard, L., Lewis, G., Matthews, K., McAllister-Williams, R., Peveler, R., Scott, J., et al. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881107088441 · Cited by 908
Ruhé, H. G., Mason, N. S., & Schene, A. H. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4001949 · Cited by 861
Cleare, A., Pariante, C., Young, A., Anderson, I., Christmas, D., Cowen, P., Dickens, C., Ferrier, I., Geddes, J., Gilbody, S., et al. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115581093 · Cited by 759
Bauer, M., Pfennig, A., Severus, E., Whybrow, P. C., Angst, J., Möller, H.-J., & Šon behalf of the Task Force on Unipolar Depressive Disorders (2013) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2013.804195 · Cited by 632
“…studies showed that the combination of a reuptake inhibitor (e.g., SSRI) with an inhibitor of presynaptic autoreceptors is more effi cacious than monotherapy with one of the antidepressants (e.g., Ferreri et al. 2001), only one study did not support this strategy (Licht and Quitzau 2002).”
BackgroundMillan, M. J. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.11.006 · Cited by 551
Metadata
- Authors
- Ferreri, M., Lavergne, F., Berlin, I., Payan, C., & Puech, A. J.
- Venue
- Acta Psychiatrica Scandinavica
- Publisher
- Wiley
- Published
- 2001-01
- Volume
- 103
- Issue
- 1
- Pages
- 66-72
- ISSN
- 0001-690X (ISSN-L)
- 1600-0447
- OpenAlex
- W1969153521
- Cited by
- 108
- References
- 2
- FWCI
- 2.40
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Benefits from mianserin augmentation of fluoxetine in patients with major depression non-responders to fluoxetine alone. https://app.cochat.ai/papers/10.1034/j.1600-0447.2001.00148.x
- The paper
- Ferreri, M., Lavergne, F., Berlin, I., Payan, C., & Puech, A. J. (2001). Benefits from mianserin augmentation of fluoxetine in patients with major depression non-responders to fluoxetine alone. Acta Psychiatrica Scandinavica. https://doi.org/10.1034/j.1600-0447.2001.00148.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.